Beta-tubulin vinca domain

The beta-tubulin vinca domain is a specific pharmacological binding site located on the beta-subunit of the tubulin heterodimer, primarily at the plus ends of microtubules (Jordan & Wilson, 2004). This domain is the target for Vinca alkaloids, which are potent anti-mitotic agents used extensively in oncology. When drugs bind to this site, they interfere with the assembly of microtubules by preventing the addition of new tubulin dimers, effectively destabilizing the polymer (Gigant et al., 2005). This disruption of microtubule dynamics prevents the formation of a functional mitotic spindle, leading to cell cycle arrest at the metaphase-anaphase transition and subsequent apoptosis. Beyond mitosis, microtubules are essential for intracellular transport and maintaining cell shape, meaning that targeting this domain also affects non-dividing cells, contributing to both therapeutic efficacy and side effects. Clinically, drugs targeting this domain are vital for treating various malignancies, including leukemias, lymphomas, and breast cancer, though their use is often limited by dose-dependent neurotoxicity (Argyriou et al., 2012).

Other names

Vinca alkaloid binding siteVinca siteTubulin vinca domainMicrotubule plus-end vinca site

Inhibition of microtubule polymerization, induction of microtubule depolymerization, and suppression of microtubule dynamics leading to mitotic arrest in metaphase (StatPearls, 2023).